At a glance
ClinicalIndex Comparison Record- ✓Age 18–65 years
- ✓Single or recurrent, non-psychotic episodes of major depressive disorder
- ✓Current episode of major depressive disorder lasting at least 8 weeks
- ✓Inadequate response to at least 1 and no more than 3 adequate antidepressant trials
None specified.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of Aripiprazole in Patients With Major Depressive Disorder
In Brief
A Phase 3 clinical trial evaluating Aripiprazole+ ADT and Placebo+ ADT for Major Depressive Disorder. Completed, enrolled 349 participants across 34 sites.
Detailed Summary
The purpose of this 14 week, randomized, double-blind, placebo controlled study is to assess the safety and efficacy of aripiprazole to placebo as adjunctive treatment to an assigned open-label marketed antidepressant therapy (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective eight week trial of the same assigned open-label marketed antidepressant therapy.
Study Details
Timeline
Interventions
Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks